Phase 1b Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Phase of Trial: Phase I
Latest Information Update: 03 Jul 2018
At a glance
- Drugs Ibrutinib (Primary) ; Lenalidomide (Primary) ; Obinutuzumab (Primary) ; Prednisone (Primary) ; Venetoclax (Primary)
- Indications B cell lymphoma
- Focus Adverse reactions
- 26 May 2018 Planned number of patients changed from 38 to 45.
- 13 Feb 2018 Planned initiation date changed from 1 Feb 2018 to 16 Feb 2018.
- 08 Feb 2018 Status changed from not yet recruiting to recruiting.